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Background: Chicken Anemia Virus (CAV) VP3 protein (also known as Apoptin), a basic and proline-rich protein has
a unique capability in inducing apoptosis in cancer cells but not in normal cells. Five truncated Apoptin proteins
were analyzed to determine their selective ability to migrate into the nucleus of human breast adenocarcinoma
MCF-7 cells for inducing apoptosis.
Methods: For identification of the minimal selective domain for apoptosis, the wild-type Apoptin gene had been
reconstructed by PCR to generate segmental deletions at the N’ terminal and linked with nuclear localization sites
(NLS1 and NLS2). All the constructs were fused with maltose-binding protein gene and individually expressed by
in vitro Rapid Translation System. Standardized dose of proteins were delivered into human breast adenocarcinoma
MCF-7 cells and control human liver Chang cells by cytoplasmic microinjection, and subsequently observed for
selective apoptosis effect.
Results: Three of the truncated Apoptin proteins with N-terminal deletions spanning amino acid 32–83 retained
the cancer selective nature of wild-type Apoptin. The proteins were successfully translocated to the nucleus of
MCF-7 cells initiating apoptosis, whereas non-toxic cytoplasmic retention was observed in normal Chang cells.
Whilst these truncated proteins retained the tumour-specific death effector ability, the specificity for MCF-7 cells
was lost in two other truncated proteins that harbor deletions at amino acid 1–31. The detection of apoptosing
normal Chang cells and MCF-7 cells upon cytoplasmic microinjection of these proteins implicated a loss in
Apoptin’s signature targeting activity.
Conclusions: Therefore, the critical stretch spanning amino acid 1–31 at the upstream of a known hydrophobic
leucine-rich stretch (LRS) was strongly suggested as one of the prerequisite region in Apoptin for cancer targeting.
Identification of this selective domain provides a platform for developing small targets to facilitating carrier-
mediated-transport across cellular membrane, simultaneously promoting protein delivery for selective and effective
breast cancer therapy.
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In the new era of biotechnology, the study in mass pro-
duction of recombinant protein has attracted a lot of at-
tention towards protein therapy which can readily
overcome the limitations faced in gene therapy and plas-
mid DNA-based vaccines. The genetic elements of plas-
mid as a propagation and expression units as well as
their host genome for the production of recombinant
plasmid DNA are still a safety concern for clinical use
[1,2]. On the other hand, protein therapy can overcome
this problem by being highly specific in action with less
potential to interfere with normal biological process and
without the need to be activated for gene expression [3].
Apoptin is a small protein of 121 amino acids (a.a.) de-
rived from chicken anemia virus (CAV) (Noteborn et al.,
[4]) and possess tumor-specific apoptosis-inducing activity.
In tumor cells, it predominantly co-localizes with hetero-
chromatin and nucleoli, followed by induction of apoptosis
in various cultured human tumorigenic and/or transformed
cell lines such as breast and lung tumor, leukemia, lymph-
oma, osteosarcoma melanoma, cholangiocarcinoma, hepa-
toma and bladder cancer cells [5,6].
Apoptin is predominantly found in the nucleus of
transformed and tumor cells, whereas in untransformed
cells, it localizes the cytoplasm. The a.a. sequence of
Apoptin contains two basic stretches constituting puta-
tive nuclear localization signals (NLS) and a stretch of
nuclear export signal (NES) [7]. The nuclear localization
regions contain a bipartite-type NLS (a.a. 82–88 and
111–121) and the distinct parts of Apoptin have inde-
pendent, intrinsic cell killing activity strongly correlated
with induction of cell death (Danen-van et al., [8]).
Whilst, NES residues at a.a. 97–105 enable the Apoptin
transportation from the nucleus to cell cytoplasm [7].
Apoptin also comprises of a hydrophobic leucine-rich
stretch (LRS) at a.a. 33–46 which assists in Apoptin
nuclear accumulation that act as nuclear retention
sequence [9].
Although popularly investigated, the mechanism of
Apoptin’s tumor-specific apoptosis activity remains to be
fully elucidated. The protein becomes specifically phos-
phorylated and activated by a kinase activity found only
in tumor or transformed cells. Apart from nuclear
targeting signals, phosphorylation site at threonine-108
(Thr-108) is pivotal in transducing apoptotic signals in
cancerous cells [10]. However, some findings reported
the partial influence of Thr-108 phosphorylation in
apoptotic activity [11,12]. Recent finding by Lanz indi-
cated the role of proteasome in Apoptin degradation but
had no influence on the amount of Apoptin in tumor
cells, although it affects p53 level. Normal cells stabilize
the Apoptin and p53 levels [13]. On other hand, Yuan L.
et al. demonstrated Apoptin bound to heat shock pro-
tein 70 (HSP70), an anti-apoptotic protein, causingdownregulation of HSP70 expression and subsequent
apoptosis induction in tumor cells. Apoptin has no effect
on HSP70 that was not activated in normal cells. Thus,
this study explained why apoptotic effect occursin tumor
cells only and not in normal cells [14].
The main aims of this study are i) to determine the
minimal functional site of Apoptin, ii) to assess the con-
tribution of LRS in the absence of NES, iii) to analyze
the early cytoplasmic events in the subcellular trafficking
of truncated Apoptins and iv) to explore the feasibility
of direct delivery of truncated Apoptins as antitumor
agents. The recombinant truncated Apoptin proteins
that were fused with maltose-binding protein (MBP) at
their N-terminus were produced by in vitro protein ex-
pression system. Maltose binding protein (MBP) fused
Apoptin exists as a stable, homogenous globular
multimeric complex, which presents the active form of
Apoptin in vivo [15]. MBP causes neither toxicity nor
apoptosis of cells. Prokaryotically expressed recombinant
MBP-Apoptin protein maintains its tumor-specific
killing and localization properties, indicating that a
mammalian-specific folding environment is not a neces-
sity [16]. In this study, we hypothesize that the presence
of minimal selective domain in truncated Apoptin com-
plexes directs the apoptotic induction in cancerous cells.
Methods
Construction of truncated MBP-apoptin plasmids
Plasmids-pIVEX-MBP (Roche Diagnostic, Germany)
was used for the expression of proteins as fusions to
the C-terminus of MBP (maltose binding protein).
PCR was conducted to amplify 5 sets of DNA frag-
ment Apoptin (Patent: PI20100031130); VP3A1-69N1N2,
VP3A1-46N1N2, VP3A1-31N1N2, VP3A32-69N1N2 and
VP3A32-62N1N2. Nine sets of primers were used to amp-
lify the DNA fragments according to the designated trunca-
tion (Figure 1). The DNA fragments were then digested
with Nco1 and Xho1 and ligated into pIVEX-MBP vectors
at the C terminus of MBP with the appropriate linkers in
between Nco1 and Xho1, generating pMBP-VP3 (a.a 1–
121), pMBP-VP3A1-69N1N2 (a.a 1–69 with NLS1 and
NLS2), pMBP-VP3A1-46N1N2 (a.a 1–46 with NLS1 and
NLS2), pMBP-VP3A1-31N1N2 (a.a. 1–31 with NLS1 and
NLS2), pMBP-VP3A32-69N1N2 (a.a. 32–69 with NLS1
and NLS2) and pMBP-VP3A32-62N1N2 (a.a. 32–62 with
NLS1 and NLS2) (Figure 1).
Protein expression
Proteins of the constructs pMBP-VP3, pMBP-VP3A1-
69N1N2, pMBP-VP3A1-46N1N2, pMBP-VP3A1-31N1N2,
pMBP-VP3A32-69N1N2 and pMBP-VP3A32-62N1N2 were
expressed by using in vitro protein synthesis system,
Rapid Translation System (RTS) (5 Prime, Germany) ac-
cording to manufacturer’s instruction. Briefly, RTS uses a
Fragment PrVP3 (Full length Apoptin) :a.a 1-121 
a.a.1 a.a. 82 a.a. 88 a.a.111 a.a. 120   a.a. 121
Fragment A (named PrVP3A1-69N1N2): 
a.a.1 a.a.69 
Fragment B (named PrVP3A1-46N1N2):
a.a.1 a.a.46
Fragment C (named PrVP3A1-31N1N2): 
a.a.1 a.a.31
Fragment D (named PrVP3A32-69N1N2): 
a.a.32 a.a.69
Fragment E (named PrVP3A32-62N1N2): 
a.a.32 a.a.61
Figure 1 Diagrammatic design of Apoptin (PrVP3) and truncated Apoptins. (PrVP3A1-69N1N2, PrVP3A1-46N1N2, PrVP3A1-31N1N2,
PrVP3A32-69N1N2, PrVP3A32-62N1N2).
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enhanced E. coli lysate to perform coupled in vitro
transcription-translation reactions.
Western blot assay
The expressed fusion proteins were separated by SDS
PAGE and confirmed via Western blot assay by using anti-
VP3 monoclonal antibody (mAb) (TropBio, Australia) and
anti-MBP mAb (New England Biolabs, USA).
Protein purification
The expressed proteins were purified by amylose resin
(New England Biolabs, USA). 300 μl of amylose resin
was added into purification column. The column was
equilibrated with 8 column volumes equilibration buffer
(10 mM Tris–HCl, pH 7.2). The expressed protein was
applied into the column by gravity flow. The column
flow was shut off after the entire sample has entered the
column. The column was incubated for 30 min. The col-
umn was washed with 10 bed volumes of wash buffer
(10 mM Tris–HCl, 1 M NaCl, pH 7.2). The protein was
eluted with 4 bed volumes of elution buffer (10 mM
Tris–HCl, 20 mM maltose, pH 7.2). The eluted protein
was concentrated using Vivaspin 2 Concentrator
(Vivascience, Germany).Cells
Experiments were performed onMCF-7 (provided by Profes-
sor Fauziah Othman, Faculty of Medicine, University Putra
Malaysia) and non-cancerous human liver cell (Chang’s cell)
(provided by Associate Professor DrZeenathul Nazariah
Allaudin, Faculty of Veterinary, University Putra Malaysia.
The maintenance medium for both cell lines contained
RPMI supplemented with 10% fetal bovine serum (FBS) and
an antibiotic solution (100 units/ml penicillin, 100 μg/ml
streptomycin). All cell culture media and supplements were
from Gibco Invitrogen Life Sciences (Paisley, UK). Both
MCF-7 cells and Chang cells were plated at a density of
2×103 onto a cover slip with size 22×22 mm2 24 h prior to
microinjection.
Microinjection
Apoptin protein was delivered into MCF-7 cells and
Chang cells through microinjection. Optimization of
cellular microinjection has been previously established
in our laboratory by using MBP protein (Lim et al., [17]).
6 μg of protein was loaded into Femtotips I (Eppendorf,
USA) by microloader and injected into the targeted cells
under an injection pressure ranging from 30–110 hPa for
0.5 s. A total number of 50 cells per cover slip were
injected.
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in rich RPMI 1640 media which contained 10% FBS
serum and incubated at 37°C in 5% CO2 incubator. The
injected cells were incubated at various time points; 2 hr
and 10 hr prior to immunofluorescence assay and 5 hr
and 15 hr before the apoptosis assay.
Immunofluorescence
The microinjected cells were fixed after incubation of
injected cells at various time points at 2 hr and 10 hr.
At different time points, the cells were fixed by im-
mersing the cover slip in 100% ice-colded methanol for
20 min at 0°C and washed thrice with PBS for 5 min
each. The cover slip was then immersed in 2 ml anti-
MBP mouse monoclonal antibody (Chemicon, USA) at
dilution 1:1000 in 10 mM PBST buffer (3.2 mM
Na2HPO4, 0.5 mM KH2PO4, 1.3 mMKCl, 135 mM
NaCl, 0.05% Tween 20, pH 7.4) at RT for an hour. The
cover slip was given again PBST buffer wash for 3 times
at 5 min each. Two ml of goat anti-mouse IgG fluores-
cein conjugated secondary antibody at dilution of 1:200
in 1M PBST was used for 1 hr at RT. Subsequently, 3
PBST washes were done for 5 min each. The FITC
stained cells were mounted with anti-fade agent and
analyzed under fluorescence microscopy (Zeiss, USA)
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Figure 2 Double digestion analysis of constructed Apoptin and
truncated Apoptin. The insert in plasmids were analysed for the
presence of the truncated inserts by double digestion with NcoI and
XhoI. Lane 1: wild-type VP3 gene with length 366 bp, lane 2: truncated
VP3 gene pMBP-VP3A1-69N1N2 with length 261 bp, lane 3: truncated
VP3 gene pMBP-VP3A1-46N1N2 with length 191 bp, lane 4: truncated
VP3 gene pMBP-VP3A1-31N1N2 with length 150 bp, Lane 5: truncated
VP3 gene pMBP-VP3A32-69N1N2 with length 174 bp and lane 6:
truncated VP3 gene pMBP-VP3A32-62N1N2 with length 150 bp. Lane
M: 50 bp DNA Ladder (New England Biolabs, USA).Apoptosis assay
Injected cells were incubated with Annexin V reagent,
ApopNexin FITC Apoptosis Detection kit (Chemicon,
USA) to detect the appearance of the apoptotic cells. At
various time points of incubation, the supernatant in the
35 mm petri dish that contained detached cells was col-
lected into a microtube and spun down at 400×g for 5
min at 4°C. The supernatant was discarded and the
pelleted cells were collected. The collected cells were
resuspended with 200 μl 1X binding buffer and spun
again at 400×g for 5 min at 4°C to collect the cells. This
step was repeated twice to wash the detached cells.
Meanwhile, those cells attached at the cover slip were
washed twice with 200 μl 1X binding buffer. After the
washing step, 200 μl of 1X binding buffer and 3 μl of
ApopNexin FITC were added into the collected cells
and mixed well. The mixture was then transferred onto
the washed coverslip and incubated for 15 min at RT.
After 15 min of incubation, 2 μl of counterstain, PI
(Chemicon, USA) was added onto the coverslip equally
and incubated again for 15 min on ice. Finally, the
coverslip that contained attached and detached (flowing)
cells were mounted with anti-fade agent, viewed under
fluorescence microscope (Zeiss, USA) and the image
captures were done by digital image analyzer.Results
Construction of truncated apoptin gene
Five truncated Apoptin fragments were amplified and
constructed in pIVEX-MBP vector. The plasmids ex-
pressing MBP and fusions of MBP and parts of Apoptin
protein have been generated. All the recombinant pro-
teins have MBP at the N terminus of Apoptin protein.
The constructed genes were named i) pMBP-VP3A1-
69N1N2 (a.a 1–69 with NLS1 and NLS2), ii) pMBP-
VP3A1-46N1N2 (a.a 1–46 with NLS1 and NLS2), iii)
pMBP-VP3A1-31N1N2 (a.a. 1–31 with NLS1 and
NLS2), iv) pMBP-VP3A32-69N1N2 (a.a. 32–69 with
NLS1 and NLS2), v) pMBP-VP3A32-62N1N2 (a.a. 32–
62 with NLS1 and NLS2) with lengths 261 bp, 191 bp,
150 bp, 174 bp and 150 bp respectively (Figure 2).
Determine translocation of truncated VP3 protein
Proteins of interest were successfully expressed using
RTS kit (5 Prime, Germany) within 6 hr of incubation
and purified by amylose resin. Western blot assay veri-
fied the presence of protein of interest (Figure 3A). The
findings showed positive expression for full-length and
truncated Apoptin proteins. Apoptin, MBP protein
(PrMBP) and its truncated proteins (PrVP3A1-69N1N2,
PrVP3A1-46N1N2 and PrVP3A1-31N1N2 were analyzed
by anti-VP3 mAb. All except for PrVP3A32-69N1N2
and PrVP3A32-62N1N2 proteins could be detected
using this mAb (Figure 3). PrVP3A32-69N1N2 and





Figure 3 In vitro protein expression of Apoptin and truncated proteins. The expressed proteins were analyzed through Western blot assay
by anti-VP3 and anti-MBP mAbs. The expressed proteins were tagged with MBP, thus showed higher molecular weight (MW) instead of the
original MW of wild-type Apoptin. The MW of Apoptin is 13.6 kDa. The MW of wild-type full length Apoptin and truncated Apoptin proteins
tagged MBP varies from 47.5-62 kDa. Lane A1: PrVP3, lane A2: PrVP3A1-69N1N2, lane A3: PrVP3A1-46N1N2 and lane A4: PrVP3A1-31N1N2 were
analysed by anti-VP3 mAb. Lane B1: PrVP3A32-69N1N2 and lane B2: PrVP3A32-62N1N2 were analyzed by anti-MBP mAb. Lane A5 and B3: Protein
Marker (NEB, UK).
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cated constructs were expressed efficiently as well as
rapidly by using in vitro protein expression system.
Detection of apoptin and truncated apoptin proteins in
injected normal and cancerous cells
Seven purified recombinant proteins including wild-type
Apoptin (PrVP3),and truncated Apoptin proteins, PrVP3A1-
69N1N2, PrVP3A1-46N1N2, PrVP3A1-31N1N2, PrVP3A32-
69N1N2, PrVP3A32-62N1N2 and negative control, PrMBP
were successfully delivered into MCF7 and Chang cell respect-
ively. The cells that were successfully microinjected with pro-
teins were shown in Figure 4 and Figure 5. All the proteins
were successfully delivered into the cytoplasm of MCF7.
Nuclear translocation was observed in cells microinjected with
wild-type Apoptin (PrVP3) and truncated Apoptin proteins,
PrVP3A1-69N1N2, PrVP3A1-46N1N2, PrVP3A1-31N1N2,
PrVP3A32-69N1N2 and PrVP3A32-62N1N2. In non-cancer-
ous Chang cells, Apoptin proteins (PrVP3), PrVP3A1-69
N1N2, PrVP3A1-46N1N2, PrVP3A1-31N1N2, PrVP3A32-
69N1N2, PrVP3A32-61N1N2 and PrMBP proteins were
found retained at the cell cytoplasm. Contrarily, nuclear trans-
location of wild-type and truncated proteins were not observ-
able at 10 hr post-microinjection.Apoptotic effect of truncated VP3 protein in MCF cells
and Chang cells
Both MCF7 cells and Chang cells were harvested at vari-
ous time points to detect the apoptotic cells (Figure 6
and Figure 7). Cells without injection (MCF-7 cells and
Chang cells) were either viable or have undergone ne-
crosis showing none or halogreen or both green and red
fluorescence signal respectively (Figures 6 and 7). PrVP3,
PrVP3A1-69N1N2, PrVP3A1-46N1N2 and PrVP3A1-
31N1N2 treatment induced apoptosis in MCF7 cells but
not in Chang cells, whilst both PrVP3A32-69N1N2 andPrVP3A32-62N1N2 caused apoptotic effect in both
MCF7 cells and Chang cells (Figure 6 and Figure 7).
The recombinant proteins, PrVP3,and PrVP3A1-
69N1N2, PrVP3A1-46N1N2,PrVP3A1-31N1N2, PrVP3A
32-69N1N2 and PrVP3A32-62N1N2 caused apoptosis in
MCF7 at 15 hr post-microinjection as shown in Figure 6.
During early hour of post-microinjection (5 hr), a few
apoptotic cells were detected in MCF7 cells. However, both
PrVP3A32-69N1N2 and PrVP3A32-69N1N2 proteins in-
duced apoptosis in Chang cells (Figure 7).
PrMBP served as the negative control to the recom-
binant Apoptin protein, where Apoptin protein and
truncated Apoptin proteins were fused to the N-
terminal of the MBP protein. As expected, PrMBP did
not cause any apoptosis effect in both cancerous cells
and normal cells. Besides, MBP protein does not have
any cytotoxic effect on cancerous cell line nor normal
cell line (Figures 6 and 7).
Discussion
In this study, the wild-type and truncated Apoptins were
delivered via cytoplasmic microinjection. To date;
needle-microinjection is widely used for the study of
many different cell responses in various fields such as
cytology, physiology, genetic engineering, molecular
biology, virology, tumor biology, developmental biology,
pharmacology and toxicology. The injected reagents in-
clude cellular organelles, proteins, enzymes, antibodies,
genes, metabolites, ions, DNA constructs, RNA, various
markers and peptides [18]. This method was of prefer-
ence over other delivery approach because i) protein
with fixed amount could be injected into the cells, ii) an
active protein could be injected into the cells instead of
transferring the plasmid into the cells for gene activation
and protein expression, and iii) a fixed number of cells
could be injected to optimize towards a standardized ap-
proach [18,19]. Therefore, direct injection of protein to








Figure 4 Indirect immunofluorescence assay on microinjected
MCF7 cells with VP3 protein and truncated VP3 protein. The
MCF7 cells were injected with A) PrVP3, B) PrVP3A1-69N1N2, C) PrVP3A1-
46N1N2, D) PrVP3A1-31N1N2 E) PrVP3A32-69N1N2, F) PrVP3A32-62N1N2
and negative control, G) PrMBP. The microinjected cells were assayed at
2 hr and 10 hr. The green fluorescence showed the present of injected
protein. At 2 hr, the injected protein was detected in the cytoplasm of
the cells (showed in red arrow), whereas the protein was found in the
nucleus of the cells at 10 hr (showed in yellow arrow) except PrMBP (G).








Figure 5 Indirect immunofluorescence assay on microinjected
Chang cells with VP3 protein and truncated VP3 protein. Chang
cells were injected with A) PrVP3, B) PrVP3A1-69N1N2, C) PrVP3A1-
46N1N2, D) PrVP3A1-31N1N2 E) PrVP3A32-69N1N2, F) PrVP3A32-
62N1N2 and negative control, G) PrMBP. The microinjected cells
were assayed at 2 hr and 10 hr. At both time points, the injected
protein (with green fluorescence) was detected at the cell cytoplasm
(shown in red arrow).
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Figure 6 Detection of Apoptotic MCF7 cells by Annexin V and
PI. MCF7 cells that were microinjected with A) PrVP3, B) PrVP3A1-
69N1N2, C) PrVP3A1-46N1N2, D) PrVP3A1-31N1N2, E) PrVP3A32-
69N1N2, F) PrVP3A32-62N1N2, G) negative control PrMBP and
H) non-injected cells were analyzed by Annexin V assay at 5 hr and
15 hr. Green fluorescence signal in the cell showed the presence of
apoptotic cells (red arrow), on the other hand the presence of both
green and red fluorescence in the cell indicated cell necrosis (yellow
arrow). Lesser apoptotic cells were observed at 5 hr than 15 hr.
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outcome of various truncated Apoptins, by passing the
possibility of loss of expression when using recombinant
plasmid or viral DNA [1,2].
This article described the generation of MBP-tagged
truncated CAV-VP3 recombinant proteins and their ef-
fect in normal and cancerous cells. Apoptin protein is
aggregated, shielded and degraded in the cytoplasm of
normal cell [20]. In transformed cells, Apoptin is
translocated into the nucleus and caused apoptosis via
activation by the tumor-specific pathway [21]. Previous
finding by Danen-van Oorschot and colleagues (2003)
indicated reduced cell killing activity upon deletion of ei-
ther N-terminal (a.a. 1–69) or C-terminal (a.a. 70–121)
halves of Apoptin. Protein consisting the N-terminal (a.a
1–69) was found in the cytoplasm whereas the C-
terminal (a.a 70–121) protein resided in cell nucleus [8].
Although, the NLS signals which shuttle the expressed
protein in the nucleus were intact in the C-terminal pro-
tein and as anticipated, the protein managed to be
translocated into the nucleus, the apoptosis effect was
still low (Danen-Van et al., [8]). Their finding was fur-
ther justified by Leliveld and associates [5].
Heilman and coworkers reveal a hydrophobic leucine-
rich stretch (LRS) at a.a. 33–46 in N-terminal which acts
as self-association region and binding region for
promyelocytic leukemia protein and other protein part-
ner [22]. This LRS has influence in nuclear accumula-
tion, whereby deletion or mutation at this region could
reduce nuclear accumulation and thus reducing the
tumor cell-specificity nuclear targeting signal-dependent
nuclear accumulation [10]. In addition to the NLSs
which resides at a.a. 82–88 and a.a. 111–121, the C-
terminal of Apoptin has a nuclear export sequence
(NES) at a.a. 97–105 [7]. NES acts as a nuclear export
signal and it is important in contributing to the ability of
the Apoptin to be strongly localized in tumor cells in-
stead of normal cells [9]. The C-terminal also consists a
phosphorylation site (Thr-108) that assists in driving
Apoptin for nuclear accumulation via inactivation of
NES in tumor cells (Rohn et al., [10]). However, Thr-108
phosphorylation has only partial effect on Apoptin’s
apoptotic activity and it is not required for the tumor-
specific nuclear localization [11].









Figure 7 Apoptosis assay in non-cancerous Chang cells. Chang
cells that were microinjected with A) PrVP3, B) PrVP3A1-69N1N2,
C) PrVP3A1-46N1N2, D) PrVP3A1-31N1N2, E) PrVP3A32-69N1N2,
F) PrVP3A32-62N1N2, G) negative control, PrMBP and H) non-
injected cells were analyzed by Annexin V assay at 5 hr and 15 hr.
Both green and red fluorescence signal in the cell showed the
presence of necrotic cells (yellow arrow). No apoptotic cell was
detected in A-D and G. Green fluorescence in E and F showed the
presence of apoptotic cells at 15 hr time point (red arrow).
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derived from the wild-type Apoptin, with each consists a
combination of selective regions at N-terminal and
NLSs. All the truncated Apoptin proteins contained both
NLSs, and the differences between them were in the
combination at N-terminal. Apoptin region at a.a. 1–69,
a.a. 1–45, a.a. 1–31, a.a. 32–69 and a.a. 32–62 were
selected to combine with NLSs respectively with the
presence of LRS (a.a. 33–46) and in the absence of NES
(a.a. 97–105) and T108. Similar to the wild-type Apoptin, all
the truncated recombinant proteins were still found at the
cytoplasm (injection site) of both cell types at the beginning
of injection (2 hr time point). Later in the event at
10 hr post-microinjection, the truncated ApoptinPrVP3A1-
69N1N2, PrVP3A1-46N1N2, and PrVP3A1-31N1N2 were
detected in the nucleus of MCF7 cells and cytoplasm of
Chang cells. This indicated the equivalent ability of those
truncated Apoptin to that of wild-type to translocate protein
to the nucleus. These truncated proteins retained the ability
in inducing apoptotic effect selectively to cancerous cells. Al-
though previous work indicated a limit in apoptotic activity
when using either N-terminal or C-terminal (Danen-Van
et al., [8]), combination of minimal functional sites from both
terminals managed to induce apoptosis in MCF-7. Neverthe-
less, due to the nature of the experiment which required in-
dividual protein injection into each cell to standardize the
injected protein dose, the number of cells investigated was
not permissive for quantitative measurement.
Intriguingly, PrVP3A32-69N1N2 and PrVP3A32-62N1N2
induced apoptosis in both MCF7 cells and Chang cells.
Both proteins had deletion at a.a. 1–31, which was an up-
stream of LRS region. Deletion of this region has led to an
unpredictable selectivity of Apoptin. In a previous study,
NES linked truncated Apoptin (a.a. 70–121) showed apop-
tosis in tumor cells but not in normal cells (Danen-von
et al., [8]). However, the present study demonstrated that
the presence of LRS in the absence of NES was sufficient to
induce apoptosis in cancerous cells, provided the upstream
of LRS (a.a. 1–31) was retained. Previously, a truncated
Apoptin lacking LRS and its upstream region (a.a. 1–31),
whilst retaining NES, NLS1, NLS2 and T108 regions man-
aged to apoptosize cancer cells selectively (Danen-von et al.,
[8]). Contrarily, this study had proven that cancerous cells
selectivity were not totally dependent on the presence
Shen Ni et al. BMC Cancer 2013, 13:488 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/488of NES. A recent study by Yang and associates showed
deletion of a.a 1–30 retained the characteristic nature of
Apoptin in the bladder cancer cells [23]. The only
significant difference between Yang’s group and ours was
the standardized microinjection-mediated-truncated pro-
tein delivery versus cell transfection of recombinant plas-
mid DNAs for expressing truncated proteins within.
Another aspect of concern would be the potential induc-
tion of apoptosis in normal cells during Apoptin abun-
dance in cytoplasm which might correlate to the nature of
transduction [24]. Successfully delivery of Apoptin into
cells and efficient expression of Apoptin are essential re-
quirements. Trans-acting activator of transcription (TAT)
protein transduction domain (PTD) has been demon-
strated to be an ideal agent of delivering Apoptin into cells
and E. coli plays an important role in expressing full length
Apoptin [25].
Trans-acting activator of transcription (TAT) protein
transduction domain (PTD) has been demonstrated to
be an ideal agent of delivering Apoptin into cells and
E. coli plays an important role in expressing full length
Apoptin [25,26].
Conclusions
We have demonstrated selective apoptosis induction in
MCF-7 cells upon standardized dose administration of
PrVP3A1-69N1N2, PrVP3A1-46N1N2, and PrVP3A1-
31N1N2. All the 3 truncated proteins consist an upstream
region from the known LRS, spanning at a.a. 1–31. The
loss of selectivity for MCF-7 cells in both PrVP3A32-
69N1N2 and PrVP3A32-62N1N2 could be implicated by
the absence of this critical region which strongly suggested
as an indispensable domain for target the apoptosis. This
study warrants further work towards quantifying the level
of apoptosis induced by these truncated proteins, with a
linked-within protein-transduction-domain (PTD).
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